Found: 30
Select item for more details and to access through your institution.
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era.
- Published in:
- Open Forum Infectious Diseases, 2021, v. 8, n. 7, p. 1, doi. 10.1093/ofid/ofab353
- By:
- Publication type:
- Article
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
- Published in:
- International Journal of Hematology, 2012, v. 96, n. 6, p. 743, doi. 10.1007/s12185-012-1192-9
- By:
- Publication type:
- Article
A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy.
- Published in:
- Supportive Care in Cancer, 2022, v. 30, n. 2, p. 1673, doi. 10.1007/s00520-021-06339-x
- By:
- Publication type:
- Article
Correlates of anxiety and depression symptoms among patients and their family caregivers prior to allogeneic hematopoietic cell transplant for hematological malignancies.
- Published in:
- 2019
- By:
- Publication type:
- journal article
FGFR1-associated myeloid neoplasm with increased mast cells.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 2, p. 172, doi. 10.1111/bjh.14533
- By:
- Publication type:
- Article
Apheresis in grade 4 bone marrow transplant associated thrombotic microangiopathy: A case series.
- Published in:
- Journal of Clinical Apheresis, 1996, v. 11, n. 4, p. 176, doi. 10.1002/(SICI)1098-1101(1996)11:4<176::AID-JCA2>3.0.CO;2-8
- By:
- Publication type:
- Article
Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 3, p. 380, doi. 10.1002/ajh.27212
- By:
- Publication type:
- Article
Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.
- Published in:
- 2011
- By:
- Publication type:
- clinical trial
Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry.
- Published in:
- Cancers, 2021, v. 13, n. 23, p. 5996, doi. 10.3390/cancers13235996
- By:
- Publication type:
- Article
Salvage of Donor Graft with Decitabine and Maintenance Post Allogeneic Stem Cell Transplantation in Myelodysplastic/Myeloproliferative Disease: A Case Report.
- Published in:
- 2009
- By:
- Publication type:
- Case Study
Outcome of acute myeloid leukemia patients with pulmonary nodules of uncertain etiology receiving allogeneic hematopoietic progenitor cell transplant.
- Published in:
- European Journal of Haematology, 2016, v. 96, n. 1, p. 55, doi. 10.1111/ejh.12547
- By:
- Publication type:
- Article
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 12, p. 882, doi. 10.1016/j.clml.2023.08.012
- By:
- Publication type:
- Article
OAB-024: Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S15, doi. 10.1016/S2152-2650(21)02098-X
- By:
- Publication type:
- Article
OAB-023: Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1–3 prior lines of therapy: Initial results from CARTITUDE-2.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S15, doi. 10.1016/S2152-2650(21)02097-8
- By:
- Publication type:
- Article
MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S422, doi. 10.1016/S2152-2650(21)01946-7
- By:
- Publication type:
- Article
Poster: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S249, doi. 10.1016/S2152-2650(21)01569-X
- By:
- Publication type:
- Article
Oral Abstract: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01275-1
- By:
- Publication type:
- Article
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS).
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 1, p. e630, doi. 10.1093/cid/ciac103
- By:
- Publication type:
- Article
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients.
- Published in:
- Clinical Infectious Diseases, 2023, v. 77, n. 5, p. 696, doi. 10.1093/cid/ciad233
- By:
- Publication type:
- Article
Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia.
- Published in:
- 2018
- By:
- Publication type:
- Letter
Peri-transplant clostridium difficile infections in patients undergoing allogeneic hematopoietic progenitor cell transplant.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 3, p. 291, doi. 10.1002/ajh.24263
- By:
- Publication type:
- Article
Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 8, p. 715, doi. 10.1002/ajh.24062
- By:
- Publication type:
- Article
Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission.
- Published in:
- Oncology Research, 2020, v. 28, n. 7/8, p. 811, doi. 10.3727/096504020X15965357399750
- By:
- Publication type:
- Article
Gemtuzumab Ozogamicin as First-Line Treatment in Patients Aged 70 Years or Older With Acute Myeloid Leukemia.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 12, p. 3001, doi. 10.1002/cncr.25078
- By:
- Publication type:
- Article
CD-19 CART therapy and orthostatic hypotension: a single center retrospective cohort study.
- Published in:
- Cardio-Oncology, 2022, v. 8, n. 1, p. 1, doi. 10.1186/s40959-022-00132-3
- By:
- Publication type:
- Article
Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation.
- Published in:
- Clinical Transplantation, 2017, v. 31, n. 9, p. n/a, doi. 10.1111/ctr.13052
- By:
- Publication type:
- Article
Hypomethylating Agents for Relapse after Allogeneic Hematopoietic Cell Transplantation in Myeloid Malignancies: A Case Series and Review of the Literature.
- Published in:
- Acta Haematologica, 2016, v. 135, n. 4, p. 232, doi. 10.1159/000444118
- By:
- Publication type:
- Article
Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma.
- Published in:
- Diagnostic Pathology, 2022, v. 17, n. 1, p. 1, doi. 10.1186/s13000-022-01244-1
- By:
- Publication type:
- Article